Clinical Trials in Massachusetts

Showing 1781-1800 of 15,316 trials

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

NCT06100991

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

Generalized Pustular Psoriasis

CorEvitas200 participantsStarted Sep 2023

Waltham, Massachusetts, United States

RECRUITING18 miles

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

NCT06562270

Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines/regulations in the country where the participating registry site is located.

Alopecia Areata

CorEvitas1,500 participantsStarted Mar 2024

Waltham, Massachusetts, United States

COMPLETEDPhase 319 miles

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

NCT06131437

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.

Obesity

Novo Nordisk A/S809 participantsStarted Nov 2023

Birmingham, Alabama, United States • Montgomery, Alabama, United States • Costa Mesa, California, United States +43 more locations

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Find Trials by Condition in Massachusetts

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Niraparib In Recurrent IDH 1/2 Gliomas

Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes

Efficacy of Routine Saline Flushing in the Prevention of Nephrostomy Tube Obstructions: A Pilot Study

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Impact of Metabolic Health on Sperm Epigenetic Marks in Humans

CLOZAPINE Response in Biotype-1

Embolization Treatment of Chronic Refractory Shoulder Tendinopathy

Vincristine Pharmacokinetics in Infants

COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

Global Registry for Endovascular Aortic Treatment (GREAT)

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma